Skip to main content
Top
Published in: Italian Journal of Pediatrics 1/2015

Open Access 01-12-2015 | Research

Metamorphic thyroid autoimmunity in Down Syndrome: from Hashimoto’s thyroiditis to Graves’ disease and beyond

Authors: Tommaso Aversa, Mariella Valenzise, Mariacarolina Salerno, Andrea Corrias, Lorenzo Iughetti, Giorgio Radetti, Filippo De Luca, Malgorzata Wasniewska

Published in: Italian Journal of Pediatrics | Issue 1/2015

Login to get access

Abstract

Background

It is known that Hashimoto’s thyroiditis (HT) may progress to Graves’ disease (GD) and that this phenomenon may be more frequent in the patients with Down syndrome (DS).

Aims

To shed light on the relationships between Down syndrome (DS) and metamorphic thyroid autoimmunity.

Patients and Methods

We reconstructed the conversion process from HT to GD in 12 DS children. All the data recorded at HT diagnosis and throughout the time interval from entry to GD presentation were retrospectively taken from patients’ files, as well as those recorded at GD diagnosis and during the subsequent evolution.
From GD diagnosis all patients underwent methimazole treatment, at a dose that was adjusted on the basis of clinical findings and thyroid tests.

Results

Time interval between HT and GD was not different in the seven patients who received during that time a L-thyroxine (L-T4) treatment than in those who were not treated. After methimazole onset all patients exhibited a prolonged remission of hyperthyroidism. In 8/12 patients this treatment is still being continued 2–7 years after its initiation. The mean methimazole dosage needed to maintain euthyroidism in these eight patients was 0.12 ± 0.02 mg/kg/day.
In the remaining four patients methimazole was withdrawn from 1.9 to 7 years after its initiation and no relapses were recorded 2.0–2.1 years after its withdrawal. These patients developed, 0.1–0.3 years after methimazole withdrawal, a picture of overt hypothyroidism and needed treatment with L-T4, that is now being continued.
No patients needed non-pharmacological therapies.

Conclusions

1) DS children might be incline to manifest over time a phenotypic metamorphosis from HT to GD and to subsequently fluctuate from hyperthyroidism to hypothyroidism; 2) in DS GD may have a mild biochemical and clinical course.
Literature
1.
go back to reference Elsheikh M, Dunger DB, Conway GS, Wass JA. Turner’s syndrome in adulthood. Endoc Rev. 2002;23:120–40. Elsheikh M, Dunger DB, Conway GS, Wass JA. Turner’s syndrome in adulthood. Endoc Rev. 2002;23:120–40.
2.
go back to reference Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with Graves’ disease treated with antithyroid agents. J Clin Invest. 1999;64:1429–36.CrossRef Wood LC, Ingbar SH. Hypothyroidism as a late sequela in patient with Graves’ disease treated with antithyroid agents. J Clin Invest. 1999;64:1429–36.CrossRef
3.
go back to reference Umar H, Muallima N, Adam JM, Sanusi H. Hashimoto’s thyroiditis following Graves’ disease. Acta Med Indones. 2010;42:31–5.PubMed Umar H, Muallima N, Adam JM, Sanusi H. Hashimoto’s thyroiditis following Graves’ disease. Acta Med Indones. 2010;42:31–5.PubMed
4.
go back to reference Champion B, Gopinath B, Ma G, El-Kaissi S, Wall JR. Conversion to Graves’ hyperthyroidism in a patient with hypothyroidism due to Hashimoto’s thyroiditis documented by real-time thyroid ultrasonography. Thyroid. 2008;18:1135–7.CrossRefPubMed Champion B, Gopinath B, Ma G, El-Kaissi S, Wall JR. Conversion to Graves’ hyperthyroidism in a patient with hypothyroidism due to Hashimoto’s thyroiditis documented by real-time thyroid ultrasonography. Thyroid. 2008;18:1135–7.CrossRefPubMed
5.
6.
go back to reference Wasniewska M, Corrias A, Arrigo T, Lombardo F, Salerno M, Mussa A, et al. Frequency of Hashimoto’s thyroiditis antecedents in the history of children and adolescents with Graves’ disease. Horm Res Paediatr. 2010;73:473–6.CrossRefPubMed Wasniewska M, Corrias A, Arrigo T, Lombardo F, Salerno M, Mussa A, et al. Frequency of Hashimoto’s thyroiditis antecedents in the history of children and adolescents with Graves’ disease. Horm Res Paediatr. 2010;73:473–6.CrossRefPubMed
7.
go back to reference Kamath C, Young S, Kabelis K, Sanders J, Adlan MA, Furmaniak J, et al. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto’s who developed Graves’ disease and pretibial myxoedema. Clin Endocrinol. 2012;77:465–70.CrossRef Kamath C, Young S, Kabelis K, Sanders J, Adlan MA, Furmaniak J, et al. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto’s who developed Graves’ disease and pretibial myxoedema. Clin Endocrinol. 2012;77:465–70.CrossRef
8.
go back to reference Majumder A, Sanyal D. A case of simultaneous occurrence of Graves’ disease and Hashimoto’s thyroiditis. Indian J Endocrinol Metab. 2012;16 Suppl 2:338–9. Majumder A, Sanyal D. A case of simultaneous occurrence of Graves’ disease and Hashimoto’s thyroiditis. Indian J Endocrinol Metab. 2012;16 Suppl 2:338–9.
9.
go back to reference Troisi A, Novati P, Sali L, Colzani M, Monti G, Cardillo C, et al. Graves’ thyrotoxicosis following Hashimoto’s thyroiditis. Res Rep Endocr Disord. 2013;3:13–5. Troisi A, Novati P, Sali L, Colzani M, Monti G, Cardillo C, et al. Graves’ thyrotoxicosis following Hashimoto’s thyroiditis. Res Rep Endocr Disord. 2013;3:13–5.
10.
go back to reference Takasu N, Matsushita M. Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients. J Thyroid Res. 2012;2012:182176.PubMedCentralCrossRefPubMed Takasu N, Matsushita M. Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients. J Thyroid Res. 2012;2012:182176.PubMedCentralCrossRefPubMed
11.
go back to reference Aversa T, Lombardo F, Corrias A, Salerno M, De Luca F, Wasniewska M. In young patients with Turner or Down syndrome, Graves’ disease presentation is often preceded by Hashimoto’s thyroiditis. Thyroid. 2014;24:744–7.CrossRefPubMed Aversa T, Lombardo F, Corrias A, Salerno M, De Luca F, Wasniewska M. In young patients with Turner or Down syndrome, Graves’ disease presentation is often preceded by Hashimoto’s thyroiditis. Thyroid. 2014;24:744–7.CrossRefPubMed
12.
go back to reference Wasniewska M, Corrias A, Salerno M, Mussa A, Capalbo D, Messina MF, et al. Thyroid function patterns at Hashimoto’s thyroiditis presentation in childhood and adolescence are mainly conditioned by patients’ age. Horm Res Paediatr. 2012;78:232–6.CrossRefPubMed Wasniewska M, Corrias A, Salerno M, Mussa A, Capalbo D, Messina MF, et al. Thyroid function patterns at Hashimoto’s thyroiditis presentation in childhood and adolescence are mainly conditioned by patients’ age. Horm Res Paediatr. 2012;78:232–6.CrossRefPubMed
13.
go back to reference Wasniewska M, Corrias A, Salerno M, Lombardo F, Aversa T, Mussa A, et al. Outcomes of children with hashitoxicosis. Horm Res Paediatr. 2012;77:36–40.CrossRefPubMed Wasniewska M, Corrias A, Salerno M, Lombardo F, Aversa T, Mussa A, et al. Outcomes of children with hashitoxicosis. Horm Res Paediatr. 2012;77:36–40.CrossRefPubMed
15.
go back to reference McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid. 2013;23:14–24.PubMedCentralCrossRefPubMed McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid. 2013;23:14–24.PubMedCentralCrossRefPubMed
16.
go back to reference Van Trotsenburg AS, Vulsma T, van Santen HM, Cheung W, de Vijlder JJ. Lower neonatal screening thyroxine concentrations in Down syndrome newborns. J Clin Endocrinol Metab. 2003;88:1512–5.CrossRefPubMed Van Trotsenburg AS, Vulsma T, van Santen HM, Cheung W, de Vijlder JJ. Lower neonatal screening thyroxine concentrations in Down syndrome newborns. J Clin Endocrinol Metab. 2003;88:1512–5.CrossRefPubMed
17.
go back to reference Van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL, Ridder JC, Heymans HS, et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005;90:3304–11.CrossRefPubMed Van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL, Ridder JC, Heymans HS, et al. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005;90:3304–11.CrossRefPubMed
18.
go back to reference Sarici D, Akin MA, Kurtoglu S, Gunes T, Ozturk MA, Akcakus M. Thyroid functions of neonates with Down syndrome. Ital J Pediatr. 2012;17:38–44. Sarici D, Akin MA, Kurtoglu S, Gunes T, Ozturk MA, Akcakus M. Thyroid functions of neonates with Down syndrome. Ital J Pediatr. 2012;17:38–44.
19.
go back to reference De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, et al. Peculiarities of Graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol. 2010;162:591–5.CrossRefPubMed De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, et al. Peculiarities of Graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol. 2010;162:591–5.CrossRefPubMed
21.
go back to reference Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto’s thyroiditis in Down’s syndrome: clinical presentation and evolution. Horm Res. 2008;70:278–84.CrossRefPubMed Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto’s thyroiditis in Down’s syndrome: clinical presentation and evolution. Horm Res. 2008;70:278–84.CrossRefPubMed
22.
go back to reference Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, Cano-Pérez JF. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol. 2009;71:110–4.CrossRef Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, Cano-Pérez JF. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol. 2009;71:110–4.CrossRef
23.
go back to reference Aversa T, Salerno M, Radetti G, Faienza MF, Iughetti L, Corrias A, et al. Peculiarities of presentation and evolution over time of Hashimoto’s thyroiditis in children and adolescents with Down’s syndrome. Hormones. 2015;14:410–6. Acceptance # 740 (2015.02.19).PubMed Aversa T, Salerno M, Radetti G, Faienza MF, Iughetti L, Corrias A, et al. Peculiarities of presentation and evolution over time of Hashimoto’s thyroiditis in children and adolescents with Down’s syndrome. Hormones. 2015;14:410–6. Acceptance # 740 (2015.02.19).PubMed
Metadata
Title
Metamorphic thyroid autoimmunity in Down Syndrome: from Hashimoto’s thyroiditis to Graves’ disease and beyond
Authors
Tommaso Aversa
Mariella Valenzise
Mariacarolina Salerno
Andrea Corrias
Lorenzo Iughetti
Giorgio Radetti
Filippo De Luca
Malgorzata Wasniewska
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2015
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-015-0197-4

Other articles of this Issue 1/2015

Italian Journal of Pediatrics 1/2015 Go to the issue